The association between nirmatrelvir plus ritonavir and the outcomes of nonhospitalized obese patients with COVID-19
Description
CONCLUSION: NMV-r can be associated with a reducing the risk of all-cause ED visits, hospitalization or death for nonhospitalized obese patients with COVID-19. Accordingly, our findings support the use of NMV-r in obese patients.
